Fairfax Holdings is a cautious buy due to its diverse asset mix, strong insurance growth, and undervaluation versus peers.

Discover why Nvidia Corporation's 44% EPS growth, AI dominance, and undervaluation signal a rare hypergrowth investment.

Research firm IDC cut its forecast for smartphone shipments this year, citing significant economic uncertainty stemming from ...

Additionally, LYB's balance sheet has quite a bit of liquidity on it, with current assets of roughly $11 billion, and ...

AOMD offers a 9.75% yield but carries high credit risk and weak performance. Explore why it may not suit conservative ...

Kaltura's Q1 2025 results beat estimates, showing improved operating leverage and near-breakeven earnings, but topline growth ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

The Make America Healthy Again Commission's report faces criticism for citing non-existent studies. Read more here.

Beam Therapeutics faces slow pipeline progress and high R&D costs despite a $500M cash boost. Learn why patience is key for ...

The John Hancock Multimanager 2025 Lifetime Portfolio fund produced a positive total return and outpaced the benchmark. Click ...

Discover how Altria outpaces the S&P 500 with steady EPS growth, strong dividends, buybacks, and emerging opportunities in ...

Opera has strong growth, high ARPU regions, and strong e-commerce ad prospects. Learn why OPRA stock is undervalued with ...